Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $25.60

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $25.60.

A number of analysts have recently issued reports on STOK shares. Chardan Capital reiterated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th.

Stoke Therapeutics Trading Down 7.6%

Shares of NASDAQ STOK opened at $8.93 on Friday. The stock has a fifty day moving average price of $8.07 and a 200 day moving average price of $10.02. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $17.58. The company has a market cap of $487.55 million, a P/E ratio of -4.25 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, May 13th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $2.27. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, sell-side analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in STOK. RTW Investments LP lifted its position in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after buying an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Stoke Therapeutics by 6.1% during the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after acquiring an additional 265,395 shares during the period. Toronto Dominion Bank bought a new position in Stoke Therapeutics in the fourth quarter worth about $35,001,000. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after acquiring an additional 53,004 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after acquiring an additional 38,446 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.